U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07252232) titled 'Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)' on Nov. 13.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Study Start Date: Dec. 10
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Resected Pancreatic Adenocarcinoma
Intervention:
DRUG: daraxonrasib
oral tablets
Recruitment Status: RECRUITING
Sponsor: Revolution Medicines, Inc.
Disclaimer: Curated by HT Synd...